We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MSBI:NASDAQMidland States Bancorp, Inc. Analysis

Data as of 2026-07-16 - not real-time

$31.70

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Midland States Bancorp (MSBI) is trading at $31.70, comfortably above its 20‑day SMA (30.44) and 50‑day SMA (28.97) while still below the 200‑day SMA (22.67), indicating a short‑term bullish bias within a longer‑term uptrend. Momentum signals are mixed: the RSI sits at 67, edging toward overbought territory, and the MACD histogram has turned negative with a bearish signal line crossover, while trading volume has been decreasing, suggesting waning short‑term enthusiasm. The stock offers an attractive 4.17% dividend yield, but the payout ratio exceeds 100%, raising concerns about sustainability. Valuation metrics are mixed – a trailing P/E of 26.4x outpaces the industry average of 18x, yet the forward P/E drops to 10.1x, and the DCF model implies a fair value far above the current price, creating a valuation paradox. Revenue growth remains robust at 14% YoY, and the forward EPS projection (3.14) more than doubles the trailing EPS (1.20), supporting a growth narrative. However, the bank’s beta (~0.8) and 30‑day volatility of nearly 25% signal higher price swings than the broader market, and the declining volume trend may limit liquidity in rapid moves. Recent material news is limited to a scheduled Q2 earnings release on July 23, providing little immediate catalyst. Overall, the stock sits at a crossroads between short‑term technical weakness and longer‑term growth fundamentals, with dividend appeal tempered by payout concerns.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance with bearish MACD crossover
  • RSI approaching overbought levels
  • Decreasing trading volume

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth and improving forward earnings
  • High dividend yield but unsustainable payout ratio
  • Valuation disparity between trailing and forward P/E

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Long‑term growth prospects in loan and wealth‑management segments
  • Potential price correction toward DCF‑derived intrinsic value
  • Low beta indicating relative resilience in broader market moves

Key Metrics & Analysis

Financial Health

Revenue Growth14.30%
Profit Margin12.81%
P/E Ratio26.4
ROE6.22%
ROA0.51%
P/B Ratio1.5
Op. Cash Flow$117.9M
Industry P/E18.0

Technical Analysis

TrendBullish
RSI67.1
Support$28.77
Resistance$31.82
MA 20$30.44
MA 50$28.97
MA 200$22.67
MACDBearish
VolumeDecreasing
Fear & Greed Index91.55

Valuation

Fair Value$76.63
Target Price$30.75
Upside/Downside-3.00%
GradeOvervalued
TypeBlend
Dividend Yield4.17%

Risk Assessment

Beta0.83
Volatility24.89%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.